Perspectives in the diagnosis and prediction of preeclampsia

Makarov O.V.; Volkova E.V.; Dzhokhadze L.S.

doi:https://doi.org/

Close metadata

Recommended articles:

Peculiarities of placental microRNA expression in patients with preeclampsia and fetal growth restriction. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):14-25

On molecular genetic predictors of preeclampsia. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):26-34

The level of hypoxia-induced factor-1a and associated molecules in preeclampsia. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):5-10

Modern concepts of preeclampsia, taking into account the role of the permeability of the hematoencephalic barrier. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):11-18

High mobility group protein B1 (HMGB1) and the potential for inflammation amplification in preeclampsia and threatened preterm labor. Russian Journal of Human Reproduction. 2024;(5):82-88

Epigenetic regulation in the placenta in case of impaired trophoblast invasion (a review). Russian Journal of Human Reproduction. 2024;(6):45-54

Morphological markers of mitochondrial dysfunction of the basal plate cytotrophoblast of the placenta in preeclampsia of varying severity. Russian Journal of Archive of Pathology. 2025;(2):24-29

Molecular mechanisms of preeclampsia. Russian Journal of Human Reproduction. 2025;(2):44-53

Impact of trophectoderm biopsy on the course of pregnancy and obstetric outcomes. Russian Journal of Human Reproduction. 2025;(3):63-69

Results of a 5-year project for the early diagnosis of multiple sclerosis in first-line blood relatives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33

Abstract:

Preeclampsia is a major cause of maternal and fetal deaths worldwide. Early identification of patients at risk for preeclampsia is one of the most important tasks of modern obstetrics. This would keep a sharp lookout for this group of pregnant women, specify the diagnosis, render timely care, take preventive measures, and simplify a set of necessary investigations. The paper analyzes an update on the pathophysiology of preeclampsia and considers a number of biochemical markers that may be used to monitor pregnant women with preeclampsia in future.

Keywords:

preeclampsia

biochemical markers

promising markers

early diagnosis

Authors:

Makarov O.V.

Kafedra akusherstva i ginekologii lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta

Volkova E.V.

Kafedra akusherstva i ginekologii lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta

Dzhokhadze L.S.

Kafedra akusherstva i ginekologii lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta

Close metadata

References:

Adya R., Tan B.K., Chen J., Randeva H.S. Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis. Atherosclerosis 2009; 205: 113-119.
Aggarwal P.K., Jain V., Sakhuja V. et al. Low urinary placental growth factor is a marker of pre-eclampsia. Kidney Int 2006; 69: 621-624.
Aksoy H., Kumtepe Y., Akcay F., Yildirim A.K. Correlation of P-selectin and lipoprotein(a), and other lipid parameters in preeclampsia. Clin Exp Med 2002; 2: 39-43.
Banzola I., Farina A., Concu M. et al. Performance of a panel of maternal serum markers in predicting preeclampsia at 11-15 weeks' gestation. Prenat Diagn 2007; 27: 1005-1010.
Bretelle F., Sabatier F., Desprez D. et al. Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb Haemost 2003; 89: 486-492.
Burger O., Pick E., Zwickel J. et al. Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta 2004; 25: 608-622.
Cetin I., Cozzi V., Pasqualini F. et al. Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction. Am J Obstet Gynec 2006; 194: 1347-1353.
Chaiworapongsa T., Romero R., Espinoza J. et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynec 2004; 190: 1541-1547.
Chaiworapongsa T., Romero R., Kim Y.M. et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3-18.
Chaiworapongsa T., Romero R., Gotsch F. et al. Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age. J Matern Fetal Neonatal Med 2008; 21: 41-52.
Chaiworapongsa T., Romero R., Yoshimatsu J. et al. Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia. J Matern Fetal Neonatal Med 2002; 12: 19-27.
Chavarria M.E., Lara-Gonzalez L., Garcia-Paleta Y. et al. Adhesion molecules changes at 20 gestation weeks in pregnancies complicated by preeclampsia. Eur J Obstet Gynecol Reprod Biol 2008; 137: 157-164.
Cowans N.J., Spencer K. First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn 2007; 27: 264-271.
Diesch C.H., Holzgreve W., Hahn S., Zhong X.Y. Comparison of activin A and cell-free fetal DNA levels in maternal plasma from patients at high risk for preeclampsia. Prenat Diagn 2006; 26: 1267-1270.
Dragun D., Muller D.N., Brasen J.H. et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558-569.
Dugoff L., Hobbins J.C., Malone F.D. et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial) Am J Obstet Gynec 2004; 191: 1446-1451.
Erez O., Romero R., Espinoza J. et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008; 21: 279-287.
Fasshauer M., Bluher M., Stumvoll M. et al. Defferential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function. Clin Endocrinol (Oxf) 2007; 66: 434-439.
Fukuhara A., Matsuda M., Nishizawa M. et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430.
Gratton R.J., Gluszynski M., Mazzuca D.M. et al. Adrenomedullin messenger ribonucleic acid expression in the placentae of normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2003; 88: 6048-6055.
Herse F., Staff A.C., Hering L. et al. AT1-receptor autoantibodies and uteroplacental RAS in pregnancy and pre-eclampsia. J Mol Med 2008; 86: 697-703.
Herse F., Verlohren S., Wenzel K. et al. Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension 2009; 53: 393-398.
Holthe M.R., Staff A.C., Berge L.N., Lyberg T. Different levels of platelet activation in preeclamptic, normotensive pregnant, and nonpregnant women. Am J Obstet Gynec 2004; 190: 1128-1134.
Hu W., Wang Z., Wang H. et al. Serum visfatin levels in late pregnancy and pre-eclampsia. Acta Obstet Gynec Scand 2008; 87: 413-418.
Huppertz B., Sammar M., Chefetz I. et al. Longitudinal determination of serum placental protein 13 during development of preeclampsia. Fetal Diagn Ther 2008; 24: 230-236.
Jeyabalan A., McGonigal S., Gilmour C. et al. Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta 2008; 29: 555-563.
Khalil A., Cowans N.J., Spencer K. et al. First trimester maternal serum placental protein 13 for the prediction of pre-eclampsia in women with a priori high risk. Prenat Diagn 2009; 8: 781-789.
Kitamura K., Kangawa K., Kawamoto M. et al. Adrenomedulli: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993; 192: 553-560.
Krantz D., Goetzl L., Simpson J.L. et al. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynec 2004; 191: 1452-1458.
Laigaard J., Sorensen T., Placing S. et al. Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. Obstet Gynec 2005; 106: 144-149.
Levine R.J., Karumanchi S.A. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynec 2005; 48: 372-386.
Levine R.J., Maynard S.E., Qian C. et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683.
Levine R.J., Qian C., LeShane E.S. et al. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynec 2004; 190: 707-713.
Levine R.J., Thadhani R., Qian C. et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005; 293: 77-85.
Lo Y.M., Corbetta N., Chamberlain P.F. et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350: 485-487.
Lok C.A., Nieuwland R., Sturk A. et al. Microparticle-associated P-selectin reflects platelet activation in preeclampsia. Platelets 2007; 18: 68-72.
Maynard S.E., Min J.Y., Merchan J. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
Moore Simas T.A., Crawford S.L. et al. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynec 2007; 197: 244-248.
Moschen A.R., Kaser A., Enrich B. et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunology 2007; 178: 1748-1758.
Nicolaides K.H., Bindra R., Turan O.M. et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynec 2006; 27: 13-17.
Poon L.C., Chelemen T., Granvillano O. et al. First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome. Obstet Gynec 2008; 112: 1082-1090.
Rana S., Karumanchi S.A., Levine R.J. et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007; 50: 137-142.
Roberts J.M., Hubel C.A. The two stage model of preeclampsia: variations on the theme. Placenta 2009; 30: 32-37.
Robinson C.J., Johnson D.D., Chang E.Y. et al. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynec 2006; 195: 255-259.
Robinson C.J., Johnson D.D. Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynec 2007; 197: 174-175.
Romero R., Kusanovic J.P., Than N.G. et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynec 2008; 199: 122.
Romero R., Nien J.K., Espinoza J. et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008; 21: 9-23.
Rovere-Querini P., Antonacci S., Dell'Antonio G. et al. Plasma and tissue expression of the long pentraxin 3 during normal pregnancy and preeclampsia. Obstet Gynec 2006; 108: 148-155.
Salahuddin S., Lee Y., Vadnais M. et al. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynec 2007; 197: 28-36.
Senna A.A., Zedan M., Salam G.E., Mashad A.I. Study of plasma adrenomedullin level in normal pregnancy and preclampsia. Medscape J Med 2008; 10: 29.
Sheng Wen Liu, Shu Bin Qiao, Jian Song Yuan, Dong Qin Liu. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol 2009; 71: 2: 202-207.
Grill S., Rusterholz C., Zanetti-Dällenbach R. et al. Potential markers of preeclampsia - a review. J Reprod Biol Endocrinol 2009; 7: 70.
Spencer K., Cowans N.J., Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn 2008; 28: 212-216.
Spencer K., Cowans N.J., Chefetz I. et al. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of preeclampsia. Ultrasound Obstet Gynec 2007; 29: 128-134.
Spencer K., Cowans N.J., Chefetz I. et al. Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of preeclampsia. Prenat Diagn 2007; 27: 258-263.
Spencer K., Cowans N.J., Nicolaides K.H. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat Diagn 2008; 28: 7-10.
Spencer K., Cowans N.J., Molina F. et al. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery. Ultrasound Obstet Gynec 2008; 31: 147-152.
Stepan H., Kramer T., Faber R. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab 2007; 92: 2831-2834.
Stepan H., Unversucht A., Wessel N., Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007; 49: 818-824.
Stepan H., Geipel A., Schwarz F. et al. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynec 2008; 198: 175-176.
Thadhani R., Mutter W.P., Wolf M. et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89: 770-775.
Tsatsaris V., Goffin F., Munaut C. et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003; 88: 5555-5563.
Venkatesha S., Toporsian M., Lam C. et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642-649.
Walther T., Wallukat G., Jank A. et al. Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension 2005; 46: 1275-1279.
Wathen K.A., Tuutti E., Stenman U.H. et al. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab 2006; 91: 180-184.
Wikstrom A.K., Larsson A., Eriksson U.J. et al. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynec 2007; 109: 1368-1374.
Zhou C.C., Ahmad S., Mi T. et al. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension 2008; 51: 1010-1019.